6
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Survival Outcome in Early-Onset Metastatic Colorectal Cancer: A Multicenter-Matched Pair Analysis

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: Survival of patients suffering from metastatic colorectal cancer (mCRC) has increased over the last decades. These benefits appear to be restricted to patients aged 50 and above. However, among the population aged <50, colorectal cancer incidence and mortality rates are significantly rising. The clinical benefit of treatment in this population still is a matter of debate. We aim to compare the clinical outcome between patients aged 50 and younger. Methods: In this retrospective, observational study, we analyzed data from 1,077 patients treated for mCRC at three cancer centers in Austria from January 2005 to December 2019. Patients were divided into two groups based on age at diagnosis: <50 years (eo-CRC) and >50 years (regular-onset CRC, ro-CRC). Propensity score matching was used to control for potential biases, and survival outcomes were compared between the two groups. Results: The differences in tumor characteristics between eo-CRC and ro-CRC in the overall population were primarily related to tumor sidedness and disease-free survival following intended curative resection. Our data show that eo-CRC patients underwent metastases resection more often and received significantly more lines of treatment in the palliative setting. Overall survival was superior in eo-CRC compared to ro-CRC, even after adjusting for sidedness, timing of metastases, sex, number of treatment lines, and resection of metastases by propensity scoring. Conclusion: Our study suggests that younger patients benefit at least to the same magnitude or even more from mCRC-treatment than patients aged 50 or above.

          Related collections

          Author and article information

          Journal
          OCL
          Oncology
          10.1159/issn.0030-2414
          Oncology
          Oncology
          S. Karger AG
          0030-2414
          1423-0232
          2024
          February 2024
          12 September 2023
          : 102
          : 2
          : 107-113
          Affiliations
          [_a] aDepartment of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology, and Medical Oncology, Ordensklinikum Linz, Linz, Austria
          [_b] bDepartment of Internal Medicine I, Wilhelminenspital, Wien, Austria
          [_c] cMedical Faculty, Johannes Kepler University Linz, Linz, Austria
          [_d] dDepartment of General and Visceral Surgery, Ordensklinikum Linz, Linz, Austria
          [_e] eGastrointestinal Cancer Center, Ordensklinikum Linz, Linz, Austria
          [_f] fDepartment of Internal Medicine IV, Hospital Wels-Grieskirchen, Wels, Austria
          Article
          533429 Oncology 2024;102:107–113
          10.1159/000533429
          37699362
          e02e546b-c9de-4ccc-a068-6327c5e13298
          © 2023 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

          History
          : 05 July 2023
          : 03 August 2023
          Page count
          Figures: 2, Tables: 2, Pages: 7
          Funding
          This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
          Categories
          Clinical Study

          Medicine
          Prognosis,Chemotherapy,Early-onset metastatic colorectal cancer,Metastatic colorectal cancer

          Comments

          Comment on this article